Axsome Therapeutics, Inc.
AXSM
$121.91
$0.260.21%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 66.04% | 81.27% | 86.65% | -20.70% | 193.50% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 66.04% | 81.27% | 86.65% | -20.70% | 193.50% |
| Cost of Revenue | 42.50% | 29.16% | 75.15% | -16.66% | 519.48% |
| Gross Profit | 68.74% | 87.91% | 87.91% | -21.05% | 176.76% |
| SG&A Expenses | 30.48% | 14.88% | 31.19% | 33.40% | 41.16% |
| Depreciation & Amortization | 0.00% | -0.06% | 0.06% | 1.08% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 42.50% | 25.73% | 54.25% | 42.11% | 60.27% |
| Operating Income | -11.92% | 25.79% | -28.61% | -950.90% | -0.82% |
| Income Before Tax | 24.40% | -2.74% | -17.05% | -691.35% | -61.62% |
| Income Tax Expenses | 126.15% | -- | -- | -- | -- |
| Earnings from Continuing Operations | 24.06% | -3.86% | -18.13% | -509.35% | -61.09% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 24.06% | -3.86% | -18.13% | -509.35% | -61.09% |
| EBIT | -11.92% | 25.79% | -28.61% | -950.90% | -0.82% |
| EBITDA | -11.69% | 27.06% | -28.73% | -1,273.94% | -0.76% |
| EPS Basic | 25.96% | -1.65% | -8.43% | -459.68% | -47.88% |
| Normalized Basic EPS | -11.62% | 25.17% | -14.77% | -627.93% | 8.49% |
| EPS Diluted | 25.96% | -1.65% | -8.43% | -459.68% | -47.88% |
| Normalized Diluted EPS | -11.62% | 25.17% | -14.77% | -627.93% | 8.49% |
| Average Basic Shares Outstanding | 2.56% | 2.17% | 8.94% | 8.89% | 8.94% |
| Average Diluted Shares Outstanding | 2.56% | 2.17% | 8.94% | 8.89% | 8.94% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
